A new study has tested the hypothesis that patients with serum antibodies against recombinant myelin oligodendrocyte glycoprotein (MOG) and purified myelin basic protein (MBP) are at an increased ...

Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune disease of the central nervous system. According to estimates, 1 to 3 in 100,000 people are affected.

(Neuron) Sex and ethnicity predicted a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD); treatment shortly after onset lowers the risk of the second event.